Highly sensitive detection of heart disease-related microRNAs using a CRISPR-based amplification method triggered by a chain reaction

The biosensing platform achieves a sub-femtomolar detection limit of 0.36 fM for specific microRNAs.

• Accurate detection of microRNAs is crucial for early diagnosis of coronary heart disease.
• The platform utilizes a dual-amplification strategy combining catalytic hairpin assembly and CRISPR/Cas12a for enhanced signal generation.
• Target microRNA initiates a cascade that produces a specific DNA product, which then activates the CRISPR/Cas12a system.
• The system demonstrates exceptional specificity through dual-sequence verification.
• Validation with spiked serum samples confirms the ability to quantify microRNA precisely.

Simplified